頁籤選單縮合
| 題 名 | 腎性貧血的評估與治療=Evaluation and Management for Anemia in Chronic Kidney Disease |
|---|---|
| 作 者 | 許育瑋; 蔡佩芬; 林慧娟; | 書刊名 | 藥學雜誌 |
| 卷 期 | 29:4=117 2013.12[民102.12] |
| 頁 次 | 頁55-61 |
| 分類號 | 415.513 |
| 關鍵詞 | 慢性腎臟病; 貧血; 紅血球生成刺激劑; Chronic kidney disease; Anemia; Erythropoiesis stimulating agents; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 貧血是慢性腎臟病 (chronic kidney disease, CKD)患者最常見的併發症,一般認為與腎臟無法產生足夠的紅血球生成素 (erythropoietin, EPO)有關,其他像是慢性出血、發炎反應、營養不良或副甲狀腺功能亢進⋯等亦可能導致貧血的情形。紅血球生成刺激劑是治療腎性貧血最主要的藥品,目前市面上所使用的紅血球生成刺激劑有多種選擇,彼此間在血紅素的提升效果上差異不大,皆藉由直接或間接結合至紅血球生成素接受體之方式以刺激紅血球生成素分泌。腎性貧血若能適時評估與治療,可以有效改善患者的生活品質與預後。 |
| 英文摘要 | Anemia is a undesirable complication that develops in most patients with Chronic Kidney Disease (CKD), several factors including chronic bleeding, inflammation, nutritional deficiencies or hyperparathyroidism are associated with anemia in CKD patients. Insufficient erythropoietin production by the kidney is generally considered as a major cause of renal anemia. Erythropoiesis stimulating agents (ESAs) increase the production of erythropoietin through direct or indirect action on the erythropoietin receptor. Currently available ESAs showed a similar efficacy on hemoglobin level achievement and played the prominent role on anemia management in CKD. For CKD patients, early assessment and management for anemia improves not only the quality of life but prognosis of patients. |
本系統中英文摘要資訊取自各篇刊載內容。